Objective: To assess the effects of the modified amino acid acetyl-dl-leucine (AL) on
cerebellar ataxia, eye movements, and quality of life of patients with Niemann-Pick type C (NP-C) …

Background The neurodegenerative lysosomal storage disorder Niemann-Pick disease type
C (NP-C) is characterized by a broad clinical variability involving neurological, psychiatric …

Niemann-Pick disease type C (NP-C) is a devastating, neurovisceral lysosomal storage
disorder which is characterised by variable manifestation of visceral signs, progressive …

Lysosomal storage disorders (LSDs) occur at a frequency of 1 in every 5,000 live births and
are a common cause of pediatric neurodegenerative disease. The relatively small number of …

Introduction This phase III, double-blind, randomised, placebo-controlled trial (and extension
phase) was designed to assess the efficacy and safety of velmanase alfa (VA) in alpha-…

Background Alpha-mannosidosis is caused by mutations in MAN2B1, leading to loss of
lysosomal alpha-mannosidase activity. Symptoms include intellectual disabilities, hearing …

Introduction Long-term outcome data provide important insights into the clinical utility of
enzyme replacement therapies. Such data are presented for velmanase alfa in the treatment of …

Objective To evaluate the clinical presentation of patients with GM1 gangliosidosis and to
determine whether specific clinical or biochemical signs could lead to a prompt diagnosis. …

GM2 and GM1 gangliosidoses are genetic, neurodegenerative lysosomal sphingolipid
storage disorders. The earlier the age of onset, the more severe the clinical presentation and …

Objective To characterize ocular motor function in patients with Niemann‐Pick disease type
C (NPC). Methods In a multicontinental, cross‐sectional study we characterized ocular‐…